Is B-type natriuretic peptide-guided heart failure management cost-effective?
- 31 August 2004
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 96 (2) , 177-181
- https://doi.org/10.1016/j.ijcard.2003.05.036
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- More evidence for bedside BNP in heart failure assessmentInternational Journal of Cardiology, 2002
- Natriuretic peptides in the diagnosis of heart disease—First amongst equals?International Journal of Cardiology, 2002
- A pharmacoeconomic evaluation of results from the coronary angioplasty amlodipine restenosis study (CAPARES) in Norway and CanadaInternational Journal of Cardiology, 2002
- BNP in hormone-guided treatment of heart failureTrends in Endocrinology & Metabolism, 2002
- Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrationsThe Lancet, 2000
- Has the survival of the heart failure population changed? lessons from trialsThe American Journal of Cardiology, 1999
- Cost effectiveness of carvedilol for heart failureThe American Journal of Cardiology, 1999
- The epidemiology of heart failure: The Framingham StudyJournal of the American College of Cardiology, 1993
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- A convenient approximation of life expectancy (the “DEALE”)The American Journal of Medicine, 1982